Non-rhabdomyosarcoma soft-tissue sarcoma

Sarah A. Milgrom, Lynn Million, Henry Mandeville, Akmal Safwat, Ralph P. Ermoian, Stephanie Terezakis

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) comprise 4% of childhood cancers and consist of numerous histologic subtypes. Prognostic factors associated with poor outcome include high histologic grade, large tumor size, presence of metastases, and unresectability. Complete surgical resection is critical for the best oncologic outcomes and is prioritized in treatment algorithms. The use of radiation therapy (RT) and chemotherapy is based upon factors such as resectability, histologic grade, tumor size, and stage. North American and European trials are defining a risk-based approach to NRSTS to limit treatment-related toxicity and to maximize therapeutic efficacy. In this paper, we summarize the current roles of surgery, RT, and chemotherapy in NRSTS and describe ongoing research that is advancing the care of NRSTS patients.

Original languageEnglish (US)
Article numbere28279
JournalPediatric Blood and Cancer
Volume68 Suppl 2
Issue numberS2
StatePublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021 Wiley Periodicals LLC


  • COG
  • SIOP
  • chemotherapy
  • non-rhabdomyosarcoma soft-tissue sarcoma
  • pazopanib
  • radiation therapy
  • sarcoma
  • surgery
  • Prognosis
  • Humans
  • Survival Rate
  • Combined Modality Therapy
  • Sarcoma/pathology
  • Child

PubMed: MeSH publication types

  • Review
  • Journal Article


Dive into the research topics of 'Non-rhabdomyosarcoma soft-tissue sarcoma'. Together they form a unique fingerprint.

Cite this